John Gilstad, MD Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: Us Naval Hospital, Psc 475 Box 1723, Fpo, AP 96350 Phone: 814-681-67816 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.
NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNSĀ® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.
"Dwindling money for research and development (R&D) and waning donor patience have forced global health players to change how they innovate new products and processes," IRIN reports.
The World Health Organization announced today that polio is no longer endemic in Nigeria. This is the first time that Nigeria has interrupted transmission of wild poliovirus, bringing the country and the African region closer than ever to being certified polio-free.
› Verified 2 days ago